User profiles for "author:Thomas Marjot"
Dr Thomas MarjotUniversity of Oxford Verified email at ndm.ox.ac.uk Cited by 3795 |
[HTML][HTML] COVID-19 and liver disease: mechanistic and clinical perspectives
Our understanding of the hepatic consequences of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection and its resultant coronavirus disease 2019 (COVID …
coronavirus 2 (SARS-CoV-2) infection and its resultant coronavirus disease 2019 (COVID …
[HTML][HTML] Non-alcoholic fatty liver disease and diabetes
Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM) are common
conditions that regularly co-exist and can act synergistically to drive adverse outcomes. The …
conditions that regularly co-exist and can act synergistically to drive adverse outcomes. The …
[HTML][HTML] Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic
During the early stages of the coronavirus disease 2019 (COVID-19) pandemic, EASL and
ESCMID published a position paper to provide guidance for physicians involved in the care …
ESCMID published a position paper to provide guidance for physicians involved in the care …
[HTML][HTML] FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Preventing SARS-CoV-2 infection by modulating viral host receptors, such as angiotensin-
converting enzyme 2 (ACE2), could represent a new chemoprophylactic approach for …
converting enzyme 2 (ACE2), could represent a new chemoprophylactic approach for …
[HTML][HTML] Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study
Background & Aims Chronic liver disease (CLD) and cirrhosis are associated with immune
dysregulation, leading to concerns that affected patients may be at risk of adverse outcomes …
dysregulation, leading to concerns that affected patients may be at risk of adverse outcomes …
High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry
[1] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality
of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet …
of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet …
[HTML][HTML] Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study
Background Despite concerns that patients with liver transplants might be at increased risk
of adverse outcomes from COVID-19 because of coexisting comorbidities and use of …
of adverse outcomes from COVID-19 because of coexisting comorbidities and use of …
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
T Marjot, A Moolla, JF Cobbold, L Hodson… - Endocrine …, 2020 - academic.oup.com
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of disease, extending from simple
steatosis to inflammation and fibrosis with a significant risk for the development of cirrhosis. It …
steatosis to inflammation and fibrosis with a significant risk for the development of cirrhosis. It …
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
T Marjot, CS Eberhardt, T Boettler, LS Belli… - Journal of …, 2022 - Elsevier
The COVID-19 pandemic has presented a serious challenge to the hepatology community,
particularly healthcare professionals and patients. While the rapid development of safe and …
particularly healthcare professionals and patients. While the rapid development of safe and …
[HTML][HTML] SARS-CoV-2 infection in patients with autoimmune hepatitis
Background & Aims Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and
coronavirus disease 2019 (COVID-19) continues to have a devastating impact across the …
coronavirus disease 2019 (COVID-19) continues to have a devastating impact across the …